

02-10-00

11

Box Seg.



EXPRESS MAIL CERTIFICATE

Date 2/9/2000 Label No. E503340112

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail" Office to Addressee" service.

D B Peck D B Peck

Name (Print)

Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

1551 U S PTO
09/501171



DARBY & DARBY P.C.

805 Third Avenue
New York, New York 10022
212-527-7700

Docket No: 1034/1F811US1

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

Enclosed please find an application for United States patent as identified below:

Inventor/s (name ALL inventors): Peter ST. GEORGE-HYSLOP; and
Paul E. FRASER

Title: PROTEINS RELATED TO NEURONAL REGENERATION AND USES THEREOF

including the items indicated:

1. Specification and 13 claims: 4 indep.; 9 dep.; 0 multiple dep.
2. Executed declaration and power of attorney
 Unexecuted declaration and power of attorney
3. Formal drawings, _ sheets (Figs.)
 Informal drawings, _ sheets (Figs.)

4. Assignment for recording to:

5. Verified Statement Claiming Small Entity Status


6. Check in amount of \$.00, (\$ filing; \$ recording; \$ surcharge)
(See attached **Fee Computation Sheet**)

7. Preliminary Amendment.

8. Please amend the description by inserting the following paragraph after the line containing the title on page 1:
"This patent application claims the priority of U.S. provisional patent application No. 60/119,835, which is incorporated herein by reference."

9. Sequence Listing. The paper (13 pp.) and electronic copies of the sequence listing are identical.

Respectfully submitted,



Paul F. Fehlner, Esq.
Reg. No. 35,135
Attorney for Applicant(s)

Serial No.

Docket No. 1034/1F811US1

PATENT FEE COMPUTATION SHEET


No. of Claims Presented	Extra Claims Previously Paid For	Number of Extra Claims	Rate
Basic Fee			\$690.00
Total Claims 13 - 20	- 0 = 0	x \$18.00	\$0.00
Independent Claims 4 - 3	- 0 = 1	x \$78.00	\$78.00
Multiple Dependent Claims	0 - if so, add	\$260.00	\$0.00
<hr/>			
Surcharge for late submission of filing fee and/or declaration (\$130.00)			\$0.00
SUBTOTAL			\$768.00
<hr/>			
[] Small Entity REDUCTION (Half of Subtotal)			\$0.00
Fee for recordation of assignment (\$40.00)			\$0.00
Charge for filing non-English language application (\$130.00)			\$0.00
TOTAL			\$768.00

EXPRESS MAIL CERTIFICATE

2/9/2000 62503340112
Date Label No.

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

D Beck


Signature

1034/1F811-US1

**PROTEINS RELATED TO NEURONAL REGENERATION
AND USES THEREOF**

FIELD OF THE INVENTION

The present invention relates generally to the treatment of neurological injury and dysfunction associated with central nervous system trauma. In particular, the invention is directed to the identification of proteins which induce neuronal regeneration.

BACKGROUND OF THE INVENTION

The peripheral nervous system (PNS) comprises highly organized groups of axon fibers or nerves external to the brain and spinal cord, such as the nerves in the limbs. In response to nerve damage, the peripheral nervous system often attempts to repair itself. While the return of lost functions is usually incomplete, generally the injured organism can adapt and function.

By contrast, damage to the central nervous system (CNS), comprising the brain and spinal cord, is generally more serious, usually causing permanent severe disability or even death.

A number of conditions are known to affect both growth and spontaneous regeneration in nerves, but the underlying mechanisms are not well understood (Gibson *et al.*, In *Compend. Contin. Educ. Pract. Vet.*, vol. 11, pp., 1989, 938–945; and Daniloff *et al.*, *J. Cell Bio.*, 1986, 103:929–945). These conditions include the location of injury, the type of injury, the severity of injury, and the age and general health of the patient.

It has been reported that minor prior recoveries somehow prime the nerve for greater recovery in secondary lesions, for example, recovery from an earlier compression injury.

There are no previous reports of an effective treatment for injuries to neurons of the central nervous system, *i.e.*, the brain and spinal cord (*see*, M. Walker, *New Engl. J. Med.*, 5 1991, 324:1885–1887.

The lack of effective treatments for nervous system injuries may be due to an insufficient understanding both of the formation of the nervous system and of its responses to injuries. Several attempts have been made to electrically stimulate injured nerves to try to cause regrowth; recovery was highly variable and inadequate (*see*, B. Sisken *et al.*, *Restorative 10 Neurology and Neuroscience*, 1990, 1:303–309; *see generally* J. Daniloff *et al.*, “The Molecular Bases of Nerve Regeneration,” in S. Malhotra (ed.), *Advances in Neural Science*, vol. 2, 1993). The method that is currently used most often to close gaps in severed nerves uses grafts of the patient's own sensory nerves, typically taken from the ankle; a minimal degree of recovery and permanent analgesia of the donor foot are the usual results.

Because an injured spinal cord has very limited ability to recover spontaneously, and because the consequences of spinal cord injuries can be so serious, there is a particular need for an effective treatment of spinal cord injuries. Paralytic spinal cord injuries in the United States alone occur at the rate of about 10,000 per year. Although the mortality rate is less than 10%, approximately 720 Americans per million population are permanently disabled as a result of spinal cord injuries. Most of the injured are young people in the most productive stage of life. 20

Following injury to neuronal cells in the central nervous system, there is often an abortive attempt by injured neural cells to generate new cellular extensions (dendrites and axons) in order to reestablish inter-neural contacts. In the central nervous system, these nerve sprouting and regeneration activities are often modest and only poorly sustained such that regeneration 25 following stroke, trauma, spinal cord injury, etc., does not usually occur.

Thus, there is a need in the art for material and methods for treating neuronal injury.

SUMMARY OF THE INVENTION

The present invention addresses this need. Applicants have surprisingly discovered that a neuron-specific armadillo protein -- Neural Plakophilin Related Armadillo Protein (NPRAP) -- causes the development of numerous long, cellular extensions, which are similar to axonal sprouting observed during neuronal regeneration and synapse formation.

One aspect of the invention is directed to a method of stimulating growth of nerve cells, which method comprises contacting the nerve cells with an hNPRAP having nerve growth stimulating activity in an amount effective to cause nerve cell growth.

In a specific embodiment related to a method of stimulating growth of nerve cells, the method comprises contacting nerve cells with an hNPRAP stimulating agent in an amount sufficient to induce the expression of an hNPRAP and cause nerve cell growth.

A further related aspect of the invention is directed to a method of stimulating neuronal regeneration in a mammal, which method comprises administering to the mammal in need thereof an effective amount of an hNPRAP or an effective amount of an hNPRAP expression stimulating agent as set forth above.

A further aspect of the invention is related to a pharmaceutical composition comprising an hNPRAP having nerve growth stimulating activity, and a pharmaceutically acceptable carrier.

Yet another aspect of the invention is related to a pharmaceutical composition comprising an hNPRAP expression stimulating agent and a pharmaceutically acceptable carrier.

In a specific embodiment, the invention provides a pharmaceutical composition comprising an hNPRAP gene therapy vector, which vector comprises a polynucleotid encoding hNPRAP and a promoter for expressing hNPRAP, and a carrier. Naturally, such gene therapy vectors are also part of the invention as well.

A further aspect of the invention relates to a method for identifying substances that modulate the expression of hNPRAP, which method comprises contacting cultured cells that express hNPRAP with a test substance measuring levels of hNPRAP, as compared to a control in

which the same cells that express hNPRAP are not contacted with the test substance, as an indication of modulatory activity of said test substance.

These and other aspects of the invention are disclosed more fully in the accompanying detailed description.

5

DETAILED DESCRIPTION

The human Neural Plakophilin Related Armadillo Protein ("hNPRAP") (also described as GT24) consensus cDNA (SEQ ID NO:3) encodes a protein (SEQ ID NO:4) of 1084 amino acid residues with a unique N-terminus, but with homology to proteins with armadillo (arm) repeat motifs at its C-terminus.

Applicants have now discovered that over-expression of hNPRAP, or functional derivatives thereof containing one or more armadillo repeats, causes the development of numerous long, dendritic processes which typically terminate upon distantly located cells. These target cells need not necessarily be expressing hNPRAP. The hNPRAP induced cellular extensions are highly similar to the axonal sprouting seen during neuronal regeneration and synapse formation.

Nucleotides 2920-2997 of the hNPRAP cDNA overlap the anonymous microsatellite locus D5S478, therefore placing the hNPRAP gene on chromosome 5p15 near the Cri-du-Chat deletion locus, a syndrome associated with congenital malformation and gross mental retardation. hNPRAP is described in detail in copending commonly assigned U.S. Application Serial Nos. 08/888,077, filed July 3, 1997 (PCT/CA97/00051), and 09/227,725, filed January 8, 1999 (PCT/CA99/00018), both of which are incorporated herein by reference.

As described in U.S. Application Serial Nos. 08/888,077 (PCT/CA97/00051) and 09/227,725 (PCT/CA99/00018), hNPRAP is known to interact with Presenilin I ("PS1") and Presenilin II ("PS2") by direct protein:protein interaction studies. The domain of the PS1 protein that interacts with hNPRAP has also been shown to interact with other proteins, such as armadillo repeat proteins p0071 and β-catenin.

On Northern blots, the hNPRAP gene is expressed as a range of transcripts of 3.9 to 5.0 kb in several regions of adult human brain, but is expressed at only very low levels in most non-neurologic tissues. Studies have shown that PS1 and hNPRAP are both expressed in the same cell types and in adjacent/contiguous subcellular compartments.

5 *In situ* hybridization studies indicate that the transcriptional pattern of PS1 and NRPAP overlap both in the brain of 4 month old mice, and in the neural tube and dorsal root ganglia of murine embryos. Both genes are expressed at high levels in dentate and hippocampal neurons, in scattered neocortical neurons, and in cerebellar Purkinje cells in adult mouse brain (Lee *et al.*, J. Neurosci., 1996, 16:7513-7525; Paffenholz and Franke, Differentiation, 1997, 10 61:293-304). Immunocytochemical studies show that PS1 and hNPRAP have overlapping intracellular distributions. Thus, in non-confluent transfected cell cultures, hNPRAP has a predominantly perinuclear cytoplasmic distribution contiguous with that of PS1. In contrast, in confluent cells with abundant cell:cell contacts, hNPRAP is predominantly located near the cell membrane close to inter-cellular contact zones while PS1 retains its predominantly perinuclear distribution.

15 The invention is directed to the use of an hNPRAP to stimulate neuronal regeneration and axon sprouting following a wide variety of insults and injuries. An "hNPRAP" is defined herein as a biologically active polypeptide that contains a sequence of hNPRAP that mediate its nerve cell growth stimulating activity, *e.g.*, the *armadillo* repeats. Thus, hNPRAP includes full-length (naturally occurring) hNPRAP, as well as biologically active analogues thereof. By "analogues" it is meant modifications such as point mutations, amino acid substitutions, additions or deletions, or other mammalian homologues, such as mouse (SEQ ID NO:5 and SEQ ID NO:6), which have similar activity to hNPRAP, the identification and selection of which are well-known to those skilled in the art. In addition to hNPRAP, the use of recombinant proteins such as p120cas and chimeric proteins having all or parts of the C-terminal armadillo-like repeat and C-terminal unique sequences of hNPRAP may also be utilized in the practice of this invention. Analogues of these proteins which replicate the effects thereof may also be utilized in the practice of this invention.

In a first embodiment, the invention provides a method of stimulating growth of nerve cells, comprising contacting nerve cells with an hNPRAP.

A second embodiment is directed to a method of stimulating growth of nerve cells, comprising contacting nerve cells with an hNPRAP stimulating agent in an amount sufficient to induce the expression of hNPRAP. Such agents may induce the expression of hNPRAP by positively binding to the hNPRAP gene to induce expression, or may alter the interaction of hNPRAP with an inhibitor of hNPRAP expression, e.g., by binding to the inhibitor itself or to hNPRAP such that the inhibitor no longer modulates the expression of hNPRAP.

Alternatively, the expression of hNPRAP may be induced by the use of an appropriate viral vector system, or by the administration of recombinant proteins, biological molecules or small molecules which simulate or resemble either the *armadillo* binding domain of the presenilins or the *armadillo* repeats of hNPRAP. Another embodiment is directed to a method for identifying substances that simulate or resemble (mimic) either the *armadillo* binding domain of the presenilins or the *armadillo* repeats of hNPRAP, and which substances cause neural growth. Candidate compounds which are shown to mimic either the *armadillo* binding domain of the presenilins or the *armadillo* repeats of hNPRAP may be produced in pharmaceutically useful quantities for use in the treatment of neurological injury and dysfunction associated with central nervous system trauma. Candidate compounds include endogenous cellular components which interact with the presenilins *in vivo* and which, therefore, provide new targets for pharmaceutical and therapeutic interventions, as well as recombinant, synthetic and otherwise exogenous compounds which may have presenilin binding capacity and, therefore, may be candidates for pharmaceutical agents. Thus, in one procedure, cell lysates or tissue homogenates (e.g., human brain homogenates, lymphocyte lysates) may be screened for proteins or other compounds which bind to one of the normal or mutant presenilins. Alternatively, any of a variety of exogenous compounds, both naturally occurring and/or synthetic (e.g., libraries of small molecules or peptides), may be screened for presenilin binding capacity. In each of these embodiments, an assay is conducted to detect binding between a presenilin component containing at least the interacting domain of a presenilin protein described herein and some other moiety.

As described in U.S. Application Serial No. 09/227,725, the presenilin domain that interacts with PS-interacting proteins, such as armadillo repeat proteins hNPRAP, p0071 and β -catenin, has been identified as including or being contained in the sequence of amino acid residues from about 260 to about 409 of PS1 or corresponding residues from about 260 to about 5 390 in PS2. More preferably, the interacting domain contains or is contained in amino acid residues from about 372 to about 399 of PS1 or corresponding residues from about 350 to about 380 in PS2. The amino acid sequences of wild-type human PS1 and PS2 are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively.

Binding may be detected by indirect functional measures reflecting the functional consequences of the interaction (*e.g.*, changes in intracellular Ca^{2+} , Na^+ , K^+ , or GTP/GDP ratio, changes in apoptosis or microtubule associated protein phosphorylation, changes in $\text{A}\beta$ peptide production or changes in the expression of other downstream genes which can be monitored by differential display, 2D gel electrophoresis, differential hybridization, or SAGE methods) or by direct measures such as immunoprecipitation, the Biomolecular Interaction Assay (BIAcore) or alteration of protein gel electrophoresis. The preferred methods involve variations on the following techniques: (1) direct extraction by affinity chromatography; (2) co-isolation of presenilin components and bound proteins or other compounds by immunoprecipitation; (3) BIAcore analysis; and (4) the yeast two-hybrid systems. Other procedures include methods which detect abnormal processing of PS1, PS2, APP, or proteins reacting with PS1, PS2, or APP (e.g., abnormal phosphorylation, glycosylation, glycation amidation or proteolytic cleavage) alterations in presenilin transcription, translation, and post-translational modification; alterations in the intracellular and extracellular trafficking of presenilin gene products; or abnormal 10 20 25 intracellular localization of the presenilins.

The proteins or other compounds identified by these methods may then be assayed for their ability to promote sprouting in axons of neuronal cultures or dendrite formation in non-neurological cells using morphometric analyses which are well-known to those skilled in the art of neuronal regeneration. Alternatively, assays for regeneration following sectioning of the optic

nerve, spinal cord, etc. in animals may be performed. Such assays are well-known to those in the field of neuronal regeneration.

The proteins or other compounds identified by these methods may be purified and characterized by any of the standard methods known in the art. Proteins may, for example, be purified and separated using electrophoretic (e.g., SDS-PAGE, 2D PAGE) or chromatographic (e.g., HPLC) techniques and may then be microsequenced. For proteins with a blocked N-terminus, cleavage (e.g., by CNBr and/or trypsin) of the particular binding protein is used to release peptide fragments. Further purification/characterization by HPLC and microsequencing and/or mass spectrometry by conventional methods provides internal sequence data on such 10 blocked proteins. For non-protein compounds, standard organic chemical analysis techniques (e.g., IR, NMR and mass spectrometry; functional group analysis; X-ray crystallography) may be employed to determine their structure and identity.

10 20 25 30 35 40 45

These hNPRAPs, and compounds which activate hNPRAP, may be employed in combination with a suitable pharmaceutical, physiologically acceptable carrier. Administration of hNPRAP of this invention can be through the administration of hNPRAP peptides agonists or antagonists synthesized from recombinant constructs of hNPRAP DNA or from peptide chemical synthesis (Woo, *et al.*, Protein Engineering, 1989, 3:29-37) or in the form of gene therapy (Goldspiel *et al.*, Clin. Pharm., 1993, 12:488; Wu and Wu, Biotherapy, 1991, 3:87; Mulligan, Science, 1993, 260:926; Morgan and Anderson, Ann. Rev. Biochem., 1993, 62:191; and, May TIBTECH, 1993, 11:155).

25

Generally, hNPRPA and/or activating agent(s) are administered as pharmaceutical compositions comprising an effective amount of hNPRAP and/or activating agent(s) in a pharmaceutical carrier. These reagents can be combined for therapeutic use with additional active or inert ingredients, e.g., in conventional pharmaceutically acceptable carriers or diluents, e.g., immunogenic adjuvants, along with physiologically innocuous stabilizers and excipients. A pharmaceutical carrier can be any compatible, non-toxic substance suitable for delivering the compositions of the invention to a patient.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Animal testing of effective doses for treatment of particular injuries will provide further predicative indication of human dosage. Various considerations are described, e.g., in Gilman *et al.* (eds.) (1990) Goodman and Gilman's; The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, PA. Methods for administration are discussed therein and below, e.g., for intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others.

Pharmaceutically acceptable carriers include water, saline, buffers and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey, and in Remington, *supra*. Slow release formulations, or a slow release apparatus, may be used for continuous administration.

Dosage ranges for hNPRAP and/or activating agent(s) would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10 μ M concentrations, usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstance is reached. Determination of the proper dosage and administration regime for a particular situation is within the skill of the art.

Polypeptides and other compounds of the present invention which activate or inhibit hNPRAP may be employed alone or in conjunction with other compounds, such as therapeutic compounds. Once identified by the methods described above, the candidate compounds may then be produced in quantities sufficient for pharmaceutical administration or testing (e.g., mg or mg or greater quantities), and formulated in a pharmaceutically acceptable carrier (*see, e.g., Remington's, supra*).

Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

The compositions of the present invention may be administered orally, parenterally, by spray inhalation, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.

Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers

include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in 5 isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known 10 in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

The methods and compositions of this invention may be used to treat nerve damage caused by a wide variety of diseases or physical traumas. These include, but are not limited to, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, stroke and ischemia associated with stroke, neural paropathy, other neural degenerative diseases, motor neuron diseases, sciatic crush, peripheral neuropathy, particularly neuropathy associated with diabetes, spinal cord injuries and facial nerve crush.

The hNPRAP polynucleotides, polypeptides, agonists and antagonists that are 20 polypeptides may be employed in accordance with the present invention by expression of such polypeptides in treatment modalities often referred to as "gene therapy". Thus, for example, cells from a patient may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*. The engineered cells can then be provided to a patient to be treated with the polypeptide. In this embodiment, cells may be engineered *ex vivo*, for example, by the use of a 25 retroviral plasmid vector containing RNA encoding a polypeptide of the present invention. Such methods are well-known in the art and their use in the present invention will be apparent from the teachings herein.

Similarly, cells may be engineered *in vivo* for expression of a polypeptide *in vivo* by procedures known in the art. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral or viral vector, as discussed above. The retroviral expression construct may then be isolated. A packaging cell is transduced with a 5 retroviral plasmid vector containing RNA encoding a polypeptide of the present invention, such that the packaging cell now produces infectious viral particles containing the gene of interest. These viral particles may be administered to a patient for engineering cells *in vivo* and expression of the polypeptide *in vivo*. These and other methods for administering a polypeptide of the present invention should be apparent to those skilled in the art from the teachings of the present 10 invention.

Retroviruses or viruses from which the plasmid vectors hereinabove-mentioned may be derived include, but are not limited to, SimiForest Virus, Lenti-virus, Moloney Murine Leukemia Virus, Spleen Necrosis Virus, Rous Sarcoma Virus, Harvey Sarcoma Virus, Avian Leukosis Virus, Gibbon Ape Leukemia Virus, Human Immunodeficiency Virus, Adenovirus, 15 Myeloproliferative Sarcoma Virus, and Mammary Tumor Virus. In a preferred embodiment, the retroviral plasmid vector is derived from Moloney Murine Leukemia Virus.

Such vectors will include one or more promoters for expressing the polypeptide. Suitable promoters which may be employed include, but are not limited to, the retroviral LTR; the 20 SV40 promoter; and the human cytomegalovirus (CMV) promoter described in Miller *et al.*, Biotechniques, 1989, 7:980-990. Cellular promoters such as eukaryotic cellular promoters including, but not limited to, the histone, RNA polymerase III, and β -actin promoters, can also be used. Additional viral promoters which may be employed include, but are not limited to, adenovirus promoters such as the adenoviral major late promoter, thymidine kinase (TK) 25 promoters such as the Herpes Simplex thymidine kinase promoters; the respiratory syncytial virus (RSV) promoters; and B19 parvovirus promoters. The selection of a suitable promoter will be apparent to those skilled in the art from the teachings contained herein.

The nucleic acid sequence encoding the polypeptide of the present invention may be placed under the control of an inducible promoter. Suitable inducible promoters which may be

employed include, but are not limited to, the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters; and human growth hormone promoters. The promoter may also be the native promoter which controls the gene encoding the polypeptide.

5 The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, .PSI.-2, .omega.-AM, PA12, T19-14X, VT-19-17-H2, .omega.CRE, .omega.CRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, A., Human Gene Therapy, 1990, 1:5-14. The vector may be transduced into the packaging cells 10 through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host. The producer cell line will generate infectious retroviral vector particles, which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles may then be employed to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express the nucleic acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

20 * * *

Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements 25 may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.

Each patent, patent application, publication, and procedure disclosed in this application is specifically incorporated by reference in its entirety.

WHAT IS CLAIMED IS:

1 1. A method of stimulating growth of nerve cells, which method comprises
2 contacting nerve cells with a human Neural Plakophilin Related *Armidillo* Protein (hNPRAP)
3 polypeptide having nerve growth stimulating activity in an amount effective to cause nerve cell
4 growth.

1 2. The method according to claim 1, wherein the hNPRAP is a full length
2 hNPRAP.

1 3. The method according to claim 2, wherein the hNPRAP has an amino acid
2 sequence as set forth in SEQ ID NO:4.

1 4. The method according to claim 1, wherein the growth of nerve cells results
2 in neuronal regeneration.

1 5. The method according to claim 4, wherein the neuronal regeneration results
2 in synapse formation.

1 6. The method according to claim 1, wherein the nerve cells are contacted
2 with an hNPRAP induced by an hNPRAP expression stimulating agent.

1 7. The method according to claim 6, wherein the hNPRAP expression
2 stimulating agent is a gene therapy vector comprising a polynucleotide encoding the hNPRAP and
3 a promoter for expressing the hNPRAP.

1 8. The method according to claim 6, wherein the growth of nerve cells results
2 in neuronal regeneration.

1 9. A pharmaceutical composition comprising an hNPRAP having nerve
2 growth stimulating activity and a carrier.

1 10. The pharmaceutical composition of claim 9, wherein the hNPRAP is a full
2 length hNPRAP.

1 11. The pharmaceutical composition of claim 10, wherein the hNPRAP has an
2 amino acid sequence as set forth in SEQ ID NO:4.

1 12. A pharmaceutical composition comprising an hNPRAP gene therapy
2 vector, which vector comprises a polynucleotide encoding the hNPRAP and a promoter for
3 expressing the hNPRAP, and a carrier.

1 13. A method of identifying substances that modulate the expression of
2 hNPRAP, which method comprises measuring the levels of hNPRAP expressed in cultured cells
3 that express hNPRAP contacted with a test substance as compared to a control, wherein a
4 difference in the level of hNPRAP expression in the cells contacted with the test substance
5 compared to the control indicates that the test substance modulates expression of hNPRAP.

ABSTRACT OF THE INVENTION

The invention provides a method for stimulating nerve growth, which also includes nerve regeneration, by contacting nerve cells with human Neural Plakophilin Related *Armadillo* Protein (hNPRAP). In a specific embodiment, hNPRAP causes the development of numerous long, cellular extensions, which are similar to axonal sprouting observed during neuronal regeneration and synapse formation. The invention further relates to pharmaceutical compositions comprising an hNPRAP, or alternatively a gene therapy vector that expresses an hNPRAP. Also provided are methods for identifying substances that modulate expression of hNPRAP.

**DECLARATION
AND POWER OF ATTORNEY**

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor if only one name is listed at 1 below, or a joint inventor if plural inventors are named below, of the invention entitled:

PROTEINS RELATED TO NEURONAL REGENERATION AND USES THEREOF

which is described and claimed in:

the attached specification or the specification in application
Serial No.
(for declaration not accompanying appl.)

(for declaration not accompanying appl.)

that I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application, that I acknowledge my duty to disclose information of which I am aware which is material to patentability in accordance with 37 CFR §1.56. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I hereby claim the priority benefits under 35 U.S.C. 119 of any application(s) for patent or inventor's certificate listed below. All foreign applications for patent or inventor's certificate on this invention filed by me or my legal representatives or assigns prior to the application(s) of which priority is claimed are also identified below.

PRIOR APPLICATION(S), IF ANY, OF WHICH PRIORITY IS CLAIMED

<u>COUNTRY</u>	<u>APPLICATION NO.</u>	<u>DATE OF FILING</u>
United States	60/119,835	February 12, 1999

**ALL FOREIGN APPLICATIONS, IF ANY, FILED PRIOR
TO THE APPLICATION(S) OF WHICH PRIORITY IS CLAIMED**

COUNTRY APPLICATION NO. DATE OF FILING

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agents(s) to prosecute this application and transact all business in the Patent and Trademark office connected therewith: Gordon D. Coplein #19,165, William F. Dudine, Jr. #20,569, Michael J. Sweedler #19,937, S. Peter Ludwig #25,351, Paul Fields #20,298, Harold E. Wurst #22,183, Joseph B. Lerch #26,936, Melvin C. Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C. Gogoris #29,714, Martin E. Goldstein #20,869, Bert J. Lewen #19,407, Henry Sternberg #22,408, Robert A. Green #28,301, Peter C. Schechter #31,662, Robert Schaffer #31,194, Robert C. Sullivan, Jr. #30,499, Ira J. Levy #35,587, Joseph R. Robinson #33,448, Jay P. Lessler #41,151, Paul F. Fehlner, #35,135

all of the firm of DARBY & DARBY P.C., 805 Third Avenue, New York, NY 10022

SEND CORRESPONDENCE TO:

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022

DIRECT TELEPHONE CALLS TO:

Paul F. Fehlner, Ph.D.
212-527-7700

FULL NAME AND RESIDENCE OF INVENTOR 1

LAST NAME: ST. GEORGE-HYSLOP

FIRST NAME: Peter

MIDDLE NAME:

CITY: Toronto, Ontario

STATE OR FOREIGN COUNTRY: CANADA

COUNTRY OF CITIZENSHIP: Canada

POST OFFICE ADDRESS: 26 Burton Road

CITY: Toronto, Ontario

STATE OR COUNTRY: Canada ZIP CODE: M5P 1T9

FULL NAME AND RESIDENCE OF INVENTOR 2

LAST NAME: FRASER

FIRST NAME: Paul

MIDDLE NAME: E.

CITY: Toronto, Ontario

STATE OR FOREIGN COUNTRY: CANADA

COUNTRY OF CITIZENSHIP: Canada

POST OFFICE ADDRESS: 611 Windermere Avenue CITY: Toronto, Ontario STATE OR COUNTRY: Canada ZIP CODE: M6S 3L9

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR : _____ DATED: _____
Peter St. GEORGE-HYSLOP

SIGNATURE OF INVENTOR : _____ DATED: _____
Paul E. FRASER

(D&D Forms/PTO-21)

SEQUENCE LISTING

<110> St. George-Hyslop, Peter H.
Fraser, Paul E.

<120> Proteins Related to Neoronal
Regeneration and Uses Thereof

<130> 1034/1F811

<160> 6

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 467
<212> PRT
<213> human

<400> 1

Met Thr Glu Leu Pro Ala Pro Leu Ser Tyr Phe Gln Asn Ala Gln Met
1 5 10 15
Ser Glu Asp Asn His Leu Ser Asn Thr Val Arg Ser Gln Asn Asp Asn
20 25 30
Arg Glu Arg Gln Glu His Asn Asp Arg Arg Ser Leu Gly His Pro Glu
35 40 45
Pro Leu Ser Asn Gly Arg Pro Gln Gly Asn Ser Arg Gln Val Val Glu
50 55 60
Gln Asp Glu Glu Glu Asp Glu Glu Leu Thr Leu Lys Tyr Gly Ala Lys
65 70 75 80
His Val Ile Met Leu Phe Val Pro Val Thr Leu Cys Met Val Val Val
80 85 90 95
Val Ala Thr Ile Lys Ser Val Ser Phe Tyr Thr Arg Lys Asp Gly Gln
100 105 110
Leu Ile Tyr Thr Pro Phe Thr Glu Asp Thr Glu Thr Val Gly Gln Arg
115 120 125
Ala Leu His Ser Ile Leu Asn Ala Ala Ile Met Ile Ser Val Ile Val
130 135 140
Val Met Thr Ile Leu Leu Val Val Leu Tyr Lys Tyr Arg Cys Tyr Lys
145 150 155 160
Val Ile His Ala Trp Leu Ile Ile Ser Ser Leu Leu Leu Phe Phe
165 170 175
Phe Ser Phe Ile Tyr Leu Gly Glu Val Phe Lys Thr Tyr Asn Val Ala
180 185 190
Val Asp Tyr Ile Thr Val Ala Leu Leu Ile Trp Asn Phe Gly Val Val
195 200 205
Gly Met Ile Ser Ile His Trp Lys Gly Pro Leu Arg Leu Gln Gln Ala
210 215 220
Tyr Leu Ile Met Ile Ser Ala Leu Met Ala Leu Val Phe Ile Lys Tyr
225 230 235 240
Leu Pro Glu Trp Thr Ala Trp Leu Ile Leu Ala Val Ile Ser Val Tyr
245 250 255

Asp Leu Val Ala Val Leu Cys Pro Lys Gly Pro Leu Arg Met Leu Val
 260 265 270
 Glu Thr Ala Gln Glu Arg Asn Glu Thr Leu Phe Pro Ala Leu Ile Tyr
 275 280 285
 Ser Ser Thr Met Val Trp Leu Val Asn Met Ala Glu Gly Asp Pro Glu
 290 295 300
 Ala Gln Arg Arg Val Ser Lys Asn Ser Lys Tyr Asn Ala Glu Ser Thr
 305 310 315 320
 Glu Arg Glu Ser Gln Asp Thr Val Ala Glu Asn Asp Asp Gly Gly Phe
 325 330 335
 Ser Glu Glu Trp Glu Ala Gln Arg Asp Ser His Leu Gly Pro His Arg
 340 345 350
 Ser Thr Pro Glu Ser Arg Ala Ala Val Gln Glu Leu Ser Ser Ser Ile
 355 360 365
 Leu Ala Gly Glu Asp Pro Glu Glu Arg Gly Val Lys Leu Gly Leu Gly
 370 375 380
 Asp Phe Ile Phe Tyr Ser Val Leu Val Gly Lys Ala Ser Ala Thr Ala
 385 390 395 400
 Ser Gly Asp Trp Asn Thr Thr Ile Ala Cys Phe Val Ala Ile Leu Ile
 405 410 415
 Gly Leu Cys Leu Thr Leu Leu Leu Ala Ile Phe Lys Lys Ala Leu
 420 425 430
 Pro Ala Leu Pro Ile Ser Ile Thr Phe Gly Leu Val Phe Tyr Phe Ala
 435 440 445
 Thr Asp Tyr Leu Val Gln Pro Phe Met Asp Gln Leu Ala Phe His Gln
 450 455 460
 Phe Tyr Ile
 465

<210> 2
 <211> 448
 <212> PRT
 <213> human

<400> 2

Met Leu Thr Phe Met Ala Ser Asp Ser Glu Glu Glu Val Cys Asp Glu
 1 5 10 15
 Arg Thr Ser Leu Met Ser Ala Glu Ser Pro Thr Pro Arg Ser Cys Gln
 20 25 30
 Glu Gly Arg Gln Gly Pro Glu Asp Gly Glu Asn Thr Ala Gln Trp Arg
 35 40 45
 Ser Gln Glu Asn Glu Glu Asp Gly Glu Glu Asp Pro Asp Arg Tyr Val
 50 55 60
 Cys Ser Gly Val Pro Gly Arg Pro Pro Gly Leu Glu Glu Leu Thr
 65 70 75 80
 Leu Lys Tyr Gly Ala Lys His Val Ile Met Leu Phe Val Pro Val Thr
 85 90 95
 Leu Cys Met Ile Val Val Val Ala Thr Ile Lys Ser Val Arg Phe Tyr
 100 105 110
 Thr Glu Lys Asn Gly Gln Leu Ile Tyr Thr Pro Phe Thr Glu Asp Thr
 115 120 125
 Pro Ser Val Gly Gln Arg Leu Leu Asn Ser Val Leu Asn Thr Leu Ile
 130 135 140

Met Ile Ser Val Ile Val Val Met Thr Ile Phe Leu Val Val Leu Tyr
 145 150 155 160
 Lys Tyr Arg Cys Tyr Lys Phe Ile His Gly Trp Leu Ile Met Ser Ser
 165 170 175
 Leu Met Leu Leu Phe Leu Phe Thr Tyr Ile Tyr Leu Gly Glu Val Leu
 180 185 190
 Lys Thr Tyr Asn Val Ala Met Asp Tyr Pro Thr Leu Leu Leu Thr Val
 195 200 205
 Trp Asn Phe Gly Ala Val Gly Met Val Cys Ile His Trp Lys Gly Pro
 210 215 220
 Leu Val Leu Gln Gln Ala Tyr Leu Ile Met Ile Ser Ala Leu Met Ala
 225 230 235 240
 Leu Val Phe Ile Lys Tyr Leu Pro Glu Trp Ser Ala Trp Val Ile Leu
 245 250 255
 Gly Ala Ile Ser Val Tyr Asp Leu Val Ala Val Leu Cys Pro Lys Gly
 260 265 270
 Pro Leu Arg Met Leu Val Glu Thr Ala Gln Glu Arg Asn Glu Pro Ile
 275 280 285
 Phe Pro Ala Leu Ile Tyr Ser Ser Ala Met Val Trp Thr Val Gly Met
 290 295 300
 Ala Lys Leu Asp Pro Ser Ser Gln Gly Ala Leu Gln Leu Pro Tyr Asp
 305 310 315 320
 Pro Glu Met Glu Glu Asp Ser Tyr Asp Ser Phe Gly Glu Pro Ser Tyr
 325 330 335
 Pro Glu Val Phe Glu Pro Pro Leu Thr Gly Tyr Pro Gly Glu Glu Leu
 340 345 350
 Glu Glu Glu Glu Arg Gly Val Lys Leu Gly Leu Gly Asp Phe Ile
 355 360 365
 Phe Tyr Ser Val Leu Val Gly Lys Ala Ala Ala Thr Gly Ser Gly Asp
 370 375 380
 Trp Asn Thr Thr Leu Ala Cys Phe Val Ala Ile Leu Ile Gly Leu Cys
 385 390 395 400
 Leu Thr Leu Leu Leu Ala Val Phe Lys Lys Ala Leu Pro Ala Leu
 405 410 415
 Pro Ile Ser Ile Thr Phe Gly Leu Ile Phe Tyr Phe Ser Thr Asp Asn
 420 425 430
 Leu Val Arg Pro Phe Met Asp Thr Leu Ala Ser His Gln Leu Tyr Ile
 435 440 445

<210> 3
 <211> 4746
 <212> DNA
 <213> human

<400> 3

gccagcatcc	cttgtccgc	ggccggctca	gacaacaaaa	gcggaaagatg	ctgcagttgg	60
gcaaggtcag	gacctgcct	tgaaagccgg	gcggcgccgc	gcaacgcctc	ttcccgact	120
gaggagctgt	cggccggcgga	gggtgcattt	ttgcgaggaa	gccgcccggc	gccgcgcctt	180
tgggagctat	gcctgttcca	gaccagcctt	catcagcctc	agagaagacg	agttccctga	240
gccccggctt	aaacacctcc	aacggggatg	gctctgaaac	agaaaccacc	tctgccatcc	300
tcgcctcagt	caaagaacag	gaattacagt	ttgaaaaggct	gaccggagag	ctggaggctg	360
aacggcagat	cgtagccagc	cagctggagc	gatgcaagct	cggatccgag	actggcagca	420
tgagcagcat	gagttcagca	gaagagcagt	ttcagtggca	gtcacaagat	ggtcaaaaag	480

atatcgaaga	ttagcttaca	acaggtctcg	agctggtgga	ctccctgtatt	aggtaactac	540
aggaatcagg	aataacttgc	ccacaggatt	attctacagg	tgaaaggccc	agcctgctct	600
cccagagtgc	acttcagctc	aattccaaac	ctgaagggtc	tttccagtt	ccggccagct	660
accatagcaa	ccagaccctg	gccctggggg	aaaccacccc	ttcacagctc	ccggcccggag	720
gcacacaagc	ccgagctacg	ggccagagct	tcagccaggg	cacgaccagc	cgccggccggcc	780
acctggcg	gccccgagccc	gcccggccgc	cgccggccgc	gccgcgggag	ccgttgcgc	840
ccagctgg	cagcgcttc	cacctgccc	acgcgcgc	cgccggccgc	gccgcggcgc	900
tctactactc	cagctccacg	ctgcccgcgc	cgccgcgcgg	gggctccccg	ctggccgcgc	960
cccagggcg	ttcgcccacc	aagctgcagc	gcggcggtc	ggcccccggag	gggcacact	1020
acgcccgc	gcccggctcc	tcgccccagg	agtgcggcag	ccgcctggcc	aagtccata	1080
gcaccagctc	gcccataac	atcgctgtgt	cctcgccgg	cctgtccccg	atccgcgtga	1140
cctcgcccc	caccgtgcag	tccaccatct	cctccctgc	catccaccag	ctgagctcca	1200
ccatcgac	gtacgcccacc	ctgtcgccca	ccaagcgctt	ggtccacgcg	tccgagcagt	1260
acagcaagca	ctcgcaggag	ctgtatgcca	cggccaccc	ccagaggccg	ggcagcctgg	1320
cagctggttc	ccgagcctca	tacagcagcc	agcatggca	cctggccca	gagttgcggg	1380
ccctgcagtc	cccagaacac	catagatc	ccatctatga	agaccgcgtc	tatcagaagc	1440
cccctatagag	gagtctcagc	cagagccagg	gggaccctct	gccgcagca	cacaccggca	1500
cctaccgcac	gagcacagcc	ccatcttccc	ctgggtgc	ctccgtcccc	ttgcagcgca	1560
caggcagcca	gcacggccca	cagaatgccc	ccgcggccac	cttccagagg	gccagctatg	1620
ccgcccggcc	aggctccaat	tacgcccggacc	cctaccgaca	gctcagttat	tgtccctctg	1680
ttgagtctcc	atacagcaaa	tccggccctg	ctctccgc	tgaaggcacc	ttggccaggt	1740
ccccgtccat	tgatagcatt	cagaaagatc	ccagagaatt	tggatggaga	gaccggaaac	1800
tgccggaagt	gattcagatg	ttgcagcacc	agttccctc	ggtccagttt	aacgcggcag	1860
ctacttgca	acacctctgt	tttggagaca	acaaaaattaa	agccgagata	aggagacaag	1920
gaggcatcca	gctcctggtg	gacctgttgg	atcatcgat	gaccgaagtc	caccgttagt	1980
ctgtggagc	tctgagaaac	ctgggttatg	ggaaggccaa	cgatgataac	aaaattgccc	2040
tgaaaaactg	tgttggcatc	ccagcactgg	tgaggttact	ccgcaagacg	actgacctgg	2100
agatccggga	gctggtcaca	ggagtcctt	ggaacctctc	ctcatgcgt	gcactcaaaa	2160
tgccaatcat	ccaggatgcc	ctagcgtac	tgaccaacgc	ggtgattatc	ccccactctag	2220
gctggggaaa	ttcgcccttt	caggatgatc	ggaaaataca	gctgcattca	tcacaggtgc	2280
tgcgtaacgc	caccgggtgc	ctaaggaatg	ttagttcggc	cgagaggag	gccgcagaa	2340
ggatgagaga	gtgtgatggg	cttacggatg	cttgtctgt	cgtgatccag	tctgcgtgg	2400
ggagcagtga	gatcgatagc	aagaccgttg	aaaactgtgt	gtgcatttt	aggaacctct	2460
tgtaccggct	ggcggcagaa	acgtctcagg	gacagcacat	ggcacggac	gagctggacg	2520
gctactctg	tggcgaggcc	aatggcaagg	atgctgagag	ctctgggtgc	tggggcaaga	2580
agaagaagaa	aaagaaatcc	caagatcgt	gggatggagt	aggaccttt	ccagactgtg	2640
ctgaaccacc	aaaagggtac	cagatgctgt	ggcacccatc	aatagtcaaa	ccctacacta	2700
cactgctctc	tgagtgtctca	aatccagaca	cgctggaaagg	ggcggcaggc	gccctgcaga	2760
acttggctgc	agggagctgg	aagtggtcag	tatatatccg	agccgctgtc	cgaaaagaga	2820
aaggcctgcc	catcctcg	gagctgtcc	gaatagacaa	tgaccgtgt	gtgtgcgcgg	2880
tggccactgc	gctgcggaaac	atggccttgg	acgtcagaaa	taaggagctc	atcgccaaat	2940
acgcccattgc	agaccttagtc	cacaggcttc	caggagggaa	caacagcaac	aacactgc	3000
gcaaggccat	gtcggtatgc	acagtgcac	ctgtctgt	cacactgcac	gaagtgatta	3060
ccaagaacat	ggagaacgccc	aaggccttac	gggatgcccgg	tggcatcgag	aagttggtcg	3120
gcatctccaa	aagcaaagga	gataaacact	ctccaaaagt	ggtcaaggct	gcatctcagg	3180
tcctcaacag	catgtggcag	taccgagatc	tgaggagtct	ctacaaaaag	gatggatggt	3240
cacaatacca	ctttgttagcc	tcgtcttcaa	ccatcgagag	ggaccggcaa	aggccctact	3300
cctcctcccg	cacggccctcc	atctccctg	tgcgctgtc	tcccaacaac	cgctcagcaa	3360
gtgccccacg	ttcacctcgg	gaaatgatca	gcctcaaaga	aaggaaaaca	gactacgagt	3420
gcaccggcag	caacgcccacc	taccacggag	ctaaaggcga	acacacttcc	aggaaagatg	3480
ccatgacagc	tcaaaaacact	ggaatttcaa	ctttgtatag	gaattctt	ggtgcgcggcc	3540
ctgaagacat	caaacacaac	caggtttcag	cacagccagt	cccacaggag	cccagcagaa	3600
aagattacga	gacctaccag	ccatccaga	attccacaag	aaattacgt	gagtccttct	3660

tcgaggacca	ggtccaccat	cgcctcccg	ccagcgagta	caccatgcac	ctgggtctca	3720
agtccaccgg	caactacgtt	gacttctact	cagctccccg	tccctacagt	gaactgaact	3780
atgaaacagag	ccactaccgg	gcctcccccgg	actcctgggt	gtgaggagca	gggcacaggc	3840
gctccgggaa	cagtgcattgt	gcatgcatac	cacaagacat	ttcttctgt	tttgttttt	3900
tctcctgaa	atttagttt	ttaaagcctg	ttccatagga	aggctgttat	aaccagtaag	3960
gaaatattaa	gagctattt	agaaagctaa	atgaatcgca	agttaacttg	gaaatcagta	4020
gaaagctaaa	gtgatcctaa	atatgacagt	gggcagcacc	tttctagcgt	gagctgtaaa	4080
gtaacgagaa	gtgctttata	ctgaacgtgg	ttgatggag	gagagacgag	gcattcgggc	4140
cgggtggggcg	taagggttat	cgttaagcac	aagacacaga	atagtttaca	cactgtgtgg	4200
gggacggcctt	ctcacgcctt	gttactctc	ttcatccgtt	gtgactctag	gcttcagggt	4260
gcattggggtt	tcctctgtac	agcaagatgt	ttcttgcctt	ttgttaatgc	attgttgtaa	4320
agtatttgc	gtacattaca	gattaaagaa	gaaaagcgcg	ttgtgtatat	tacaccaatg	4380
ccgcccgttt	tcctcatcta	tggttctaaa	tattgctca	atttcaaact	tttgaaagat	4440
gtatggattt	ccagtttttc	tttactttct	cccagtatgt	tttaacaaaa	aaaaaaaaaa	4500
gcaggaaaaaa	aggaatattt	agcagtattt	ttcgttctga	tatgtgaatt	tgttgtgac	4560
aactaaacaa	ggcattcagc	agtttctgac	aattaacata	catcattcca	cactccttgt	4620
caacaaaagt	ctttttcact	gcctaaaattt	tttagatgttag	atatttggaa	tagattttt	4680
catttataacc	agttttcttt	atgatgatac	agtgttaaaa	gaaaataaaat	tacaatttgat	4740
ctgtca						4746

<210> 4
 <211> 1225
 <212> PRT
 <213> human

<400> 4

Met	Phe	Ala	Arg	Lys	Pro	Pro	Gly	Ala	Ala	Pro	Leu	Gly	Ala	Met	Pro
1					5					10				15	
Val	Pro	Asp	Gln	Pro	Ser	Ser	Ala	Ser	Glu	Lys	Thr	Ser	Ser	Leu	Ser
					20				25					30	
Pro	Gly	Leu	Asn	Thr	Ser	Asn	Gly	Asp	Gly	Ser	Glu	Thr	Glu	Thr	Thr
					35				40					45	
Ser	Ala	Ile	Leu	Ala	Ser	Val	Lys	Glu	Gln	Glu	Leu	Gln	Phe	Glu	Arg
					50			55			60				
Leu	Thr	Arg	Glu	Leu	Glu	Ala	Glu	Arg	Gln	Ile	Val	Ala	Ser	Gln	Leu
					65			70		75					80
Glu	Arg	Cys	Lys	Leu	Gly	Ser	Glu	Thr	Gly	Ser	Met	Ser	Ser	Met	Ser
					85				90						95
Ser	Ala	Glu	Glu	Gln	Phe	Gln	Trp	Gln	Ser	Gln	Asp	Gly	Gln	Lys	Asp
					100			105							110
Ile	Glu	Asp	Glu	Leu	Thr	Thr	Gly	Leu	Glu	Leu	Val	Asp	Ser	Cys	Ile
					115			120							125
Arg	Ser	Leu	Gln	Glu	Ser	Gly	Ile	Leu	Asp	Pro	Gln	Asp	Tyr	Ser	Thr
					130			135							140
Gly	Glu	Arg	Pro	Ser	Leu	Leu	Ser	Gln	Ser	Ala	Leu	Gln	Leu	Asn	Ser
					145			150							160
Lys	Pro	Glu	Gly	Ser	Phe	Gln	Tyr	Pro	Ala	Ser	Tyr	His	Ser	Asn	Gln
					165				170						175
Thr	Leu	Ala	Leu	Gly	Glu	Thr	Thr	Pro	Ser	Gln	Leu	Pro	Ala	Arg	Gly
					180				185						190
Thr	Gln	Ala	Arg	Ala	Thr	Gly	Gln	Ser	Phe	Ser	Gln	Gly	Thr	Thr	Ser
					195				200						205
Arg	Ala	Gly	His	Leu	Ala	Gly	Pro	Glu	Pro	Ala	Pro	Pro	Pro	Pro	Pro

210	215	220
Pro	Pro	Arg Glu Pro Phe Ala Pro Ser Leu Gly Ser Ala Phe His Leu
225	230	235 240
Pro	Asp Ala Pro Pro Ala Ala Ala Ala Leu Tyr Tyr Ser Ser	
	245	250 255
Ser	Thr Leu Pro Ala Pro Pro Arg Gly Gly Ser Pro Leu Ala Ala Pro	
	260	265 270
Gln	Gly Gly Ser Pro Thr Lys Leu Gln Arg Gly Gly Ser Ala Pro Glu	
	275	280 285
Gly	Ala Thr Tyr Ala Ala Pro Arg Gly Ser Ser Pro Lys Gln Ser Pro	
	290	295 300
Ser	Arg Leu Ala Lys Ser Tyr Ser Thr Ser Ser Pro Ile Asn Ile Val	
305	310	315 320
Val	Ser Ser Ala Gly Leu Ser Pro Ile Arg Val Thr Ser Pro Pro Thr	
	325	330 335
Val	Gln Ser Thr Ile Ser Ser Ser Pro Ile His Gln Leu Ser Ser Thr	
	340	345 350
Ile	Gly Thr Tyr Ala Thr Leu Ser Pro Thr Lys Arg Leu Val His Ala	
	355	360 365
Ser	Glu Gln Tyr Ser Lys His Ser Gln Glu Leu Tyr Ala Thr Ala Thr	
	370	375 380
Leu	Gln Arg Pro Gly Ser Leu Ala Ala Gly Ser Arg Ala Ser Tyr Ser	
385	390	395 400
Ser	Gln His Gly His Leu Gly Pro Glu Leu Arg Ala Leu Gln Ser Pro	
	405	410 415
Glu	His His Ile Asp Pro Ile Tyr Glu Asp Arg Val Tyr Gln Lys Pro	
	420	425 430
Pro	Met Arg Ser Leu Ser Gln Ser Gln Gly Asp Pro Leu Pro Pro Ala	
	435	440 445
His	Thr Gly Thr Tyr Arg Thr Ser Thr Ala Pro Ser Ser Pro Gly Val	
	450	455 460
Asp	Ser Val Pro Leu Gln Arg Thr Gly Ser Gln His Gly Pro Gln Asn	
465	470	475 480
Ala	Ala Ala Ala Ala Thr Phe Gln Arg Ala Ser Tyr Ala Ala Gly Pro Ala	
	485	490 495
Ser	Asn Tyr Ala Asp Pro Tyr Arg Gln Leu Gln Tyr Cys Pro Ser Val	
	500	505 510
Glu	Ser Pro Tyr Ser Lys Ser Gly Pro Ala Leu Pro Pro Glu Gly Thr	
	515	520 525
Leu	Ala Arg Ser Pro Ser Ile Asp Ser Ile Gln Lys Asp Pro Arg Glu	
	530	535 540
Phe	Gly Trp Arg Asp Pro Glu Leu Pro Glu Val Ile Gln Met Leu Gln	
545	550	555 560
His	Gln Phe Pro Ser Val Gln Ser Asn Ala Ala Ala Tyr Leu Gln His	
	565	570 575
Leu	Cys Phe Gly Asp Asn Lys Ile Lys Ala Glu Ile Arg Arg Gln Gly	
	580	585 590
Gly	Ile Gln Leu Leu Val Asp Leu Leu Asp His Arg Met Thr Glu Val	
	595	600 605
His	Arg Ser Ala Cys Gly Ala Leu Arg Asn Leu Val Tyr Gly Lys Ala	
	610	615 620
Asn	Asp Asp Asn Lys Ile Ala Leu Lys Asn Cys Gly Gly Ile Pro Ala	
625	630	635 640

Leu Val Arg Leu Leu Arg Lys Thr Thr Asp Leu Glu Ile Arg Glu Leu
 645 650 655
 Val Thr Gly Val Leu Trp Asn Leu Ser Ser Cys Asp Ala Leu Lys Met
 660 665 670
 Pro Ile Ile Gln Asp Ala Leu Ala Val Leu Thr Asn Ala Val Ile Ile
 675 680 685
 Pro His Ser Gly Trp Glu Asn Ser Pro Leu Gln Asp Asp Arg Lys Ile
 690 695 700
 Gln Leu His Ser Ser Gln Val Leu Arg Asn Ala Thr Gly Cys Leu Arg
 705 710 715 720
 Asn Val Ser Ser Ala Gly Glu Glu Ala Arg Arg Arg Met Arg Glu Cys
 725 730 735
 Asp Gly Leu Thr Asp Ala Leu Leu Tyr Val Ile Gln Ser Ala Leu Gly
 740 745 750
 Ser Ser Glu Ile Asp Ser Lys Thr Val Glu Asn Cys Val Cys Ile Leu
 755 760 765
 Arg Asn Leu Ser Tyr Arg Leu Ala Ala Glu Thr Ser Gln Gly Gln His
 770 775 780
 Met Gly Thr Asp Glu Leu Asp Gly Leu Leu Cys Gly Glu Ala Asn Gly
 785 790 795 800
 Lys Asp Ala Glu Ser Ser Gly Cys Trp Gly Lys Lys Lys Lys Lys
 805 810 815
 Lys Ser Gln Asp Gln Trp Asp Gly Val Gly Pro Leu Pro Asp Cys Ala
 820 825 830
 Glu Pro Pro Lys Gly Ile Gln Met Leu Trp His Pro Ser Ile Val Lys
 835 840 845
 Pro Tyr Leu Thr Leu Leu Ser Glu Cys Ser Asn Pro Asp Thr Leu Glu
 850 855 860
 Gly Ala Ala Gly Ala Leu Gln Asn Leu Ala Ala Gly Ser Trp Lys Trp
 865 870 875 880
 Ser Val Tyr Ile Arg Ala Ala Val Arg Lys Glu Lys Gly Leu Pro Ile
 885 890 895
 Leu Val Glu Leu Leu Arg Ile Asp Asn Asp Arg Val Val Cys Ala Val
 900 905 910
 Ala Thr Ala Leu Arg Asn Met Ala Leu Asp Val Arg Asn Lys Glu Leu
 915 920 925
 Ile Gly Lys Tyr Ala Met Arg Asp Leu Val His Arg Leu Pro Gly Gly
 930 935 940
 Asn Asn Ser Asn Asn Thr Ala Ser Lys Ala Met Ser Asp Asp Thr Val
 945 950 955 960
 Thr Ala Val Cys Cys Thr Leu His Glu Val Ile Thr Lys Asn Met Glu
 965 970 975
 Asn Ala Lys Ala Leu Arg Asp Ala Gly Gly Ile Glu Lys Leu Val Gly
 980 985 990
 Ile Ser Lys Ser Lys Gly Asp Lys His Ser Pro Lys Val Val Lys Ala
 995 1000 1005
 Ala Ser Gln Val Leu Asn Ser Met Trp Gln Tyr Arg Asp Leu Arg Ser
 1010 1015 1020
 Leu Tyr Lys Lys Asp Gly Trp Ser Gln Tyr His Phe Val Ala Ser Ser
 1025 1030 1035 104
 Ser Thr Ile Glu Arg Asp Arg Gln Arg Pro Tyr Ser Ser Ser Arg Thr
 1045 1050 1055
 Pro Ser Ile Ser Pro Val Arg Val Ser Pro Asn Asn Arg Ser Ala Ser

1060	1065	1070
Ala Pro Ala Ser Pro Arg Glu Met Ile Ser Leu Lys	Glu Arg Lys Thr	
1075	1080	1085
Asp Tyr Glu Cys Thr Gly Ser Asn Ala Thr Tyr His	Gly Ala Lys Gly	
1090	1095	1100
Glu His Thr Ser Arg Lys Asp Ala Met Thr Ala Gln	Asn Thr Gly Ile	
1105	1110	1115
Ser Thr Leu Tyr Arg Asn Ser Tyr Gly Ala Pro Ala	Glu Asp Ile Lys	
1125	1130	1135
His Asn Gln Val Ser Ala Gln Pro Val Pro Gln Glu	Pro Ser Arg Lys	
1140	1145	1150
Asp Tyr Glu Thr Tyr Gln Pro Phe Gln Asn Ser Thr	Arg Asn Tyr Asp	
1155	1160	1165
Glu Ser Phe Phe Glu Asp Gln Val His His Arg	Pro Pro Ala Ser Glu	
1170	1175	1180
Tyr Thr Met His Leu Gly Leu Lys Ser Thr Gly Asn	Tyr Val Asp Phe	
1185	1190	1195
Tyr Ser Ala Ala Arg Pro Tyr Ser Glu Leu Asn	Tyr Glu Thr Ser His	
1205	1210	1215
Tyr Pro Ala Ser Pro Asp Ser Trp Val		
1220	1225	

<210> 5
<211> 4998
<212> DNA
<213> mouse

<400> 5

aagcgccgga	gccggccgccc	gcggctgagc	cggaggctga	gctgcggcgc	gcggcgggag	60
gagcctcgct	ctcggcggcg	gcggcggcgg	cggcgacaca	ggtggcgcgg	gcggcgcgc	120
gggcgcagct	cgagagcgt	cggcgccggg	cgccaggcg	gcccaggctc	gagccgcgg	180
gggcgcaccgg	ccgagcggag	cggcgccgc	ggcggctcg	tagcccgcc	cgagcccggg	240
gagcccccg	gaacccttag	catcccgcgg	cgcccggca	gtcgggcagg	gggcgtacg	300
ctcgccgcgc	tccggagggc	ggccgggccc	ggcgctgcgc	actcgctcg	ggagccgcct	360
ctcgccctgccc	gcgctcgccc	ctgtcccccg	ccagcatcac	ttgtcccg	ggcgctcc	420
gacaacaaaa	gcccggatg	ctgcagctgg	gcaaggtcag	gaccttgc	tgaagccggg	480
ccggcggcgc	cacgccttcc	ccccgactga	ggagctgtct	ttggcggcgg	gtgcatttc	540
gccaggaagc	agtccggcgc	cgcgcgttc	ggagctatgc	ctgtcccaga	ccagcccca	600
tcagcctcag	agaagaacag	ctccttgagc	ccaggcttaa	acaccccaa	ttgttatggc	660
tctgagacgg	aaaccaccc	tgctatcctt	gcctccgtca	aagaacagga	attacat	720
gaaaggctga	cccgagagct	ggaggctgaa	cgccagatcg	tagccagcca	gctggagcga	780
tgcaagcttgc	gctcggagac	aggaagcatg	agcagtatca	tttcagcagg	agagcagttt	840
cactggcaga	cacaagatgg	ccaaaagat	atcgaagatg	aacttacaac	gggcctttag	900
ctggtggtact	cctgtatcc	ctctctgcag	gagtcaggca	ttctggaccc	acaggattac	960
tccacaagtgc	aaaggcttag	cctgctctcc	cagagtgcac	ttcagctaa	ttctaaacct	1020
gaagggtctt	tccagtatcc	ggccagctac	catagcaacc	agacccctggc	cctgggtgac	1080
acagccctt	ctcagctccc	agcacgcagc	acgcaagccc	gagctccgg	ccagagctc	1140
agccaggcgc	cgaccggccg	cgccgggcac	ctggcgggct	ccgagcctgc	gccaccgc	1200
ccgcctccgc	ggaaaccgtt	cgccccagc	ctggcagcg	ccttccacct	gcccgcacgc	1260
ccgccccccgc	ccgcggcgct	ctactactcc	agctccacgc	tgcccgcc	ggcgccggg	1320
ggctcccccgc	tgaccaccac	gcagggcggc	tcacccacca	agctgcagcg	cgaggctcg	1380
gccccccgagg	gtgcccgccta	cgccgcgcgc	cgcggctcct	cgcacaagca	gtcgcccagc	1440
cgccctggcta	agtccctacag	caccagctcg	cccatcaaca	tcgtcggtc	ctcgccggc	1500

ctgtccccga	tccgcgtgac	ctcgccccc	accgtgcagt	ccaccatctc	ctcttcgccc	1560
atccaccagc	tgagctccac	catcgccacc	tacgccaccc	tgtcgcccac	caagcgccctg	1620
gtccacgcgt	ctgagcagta	cagaagcat	tcgcaggagc	tgtatgccac	cgccaccctc	1680
cagaggccgg	gcagcctggc	agctggatcc	cgagcctcgt	atagcagcca	gcatgggcac	1740
ctggccctg	agctgcgggc	cctgcagtc	ccagagcacc	acatagaccc	catctatgaa	1800
gaccgtgtct	atcagaagcc	ccctatgagg	agtctcagcc	agagccaggg	ggatcctctg	1860
ccgcccagcac	ataccggcac	cttccgcacg	agcacagccc	cgtccctccc	tggtgtcgac	1920
tccgtccct	tgcagcgcac	aggcagccaa	cacgggcccac	agaatgccgc	cgcagccacc	1980
ttccagaggg	ccagctatgc	tgcgggccc	gcctccaact	acgcagaccc	ctaccgacag	2040
ctgcagtatt	gtgcctccgt	tgactctccg	tacagcaaat	ctggccctgc	cctcccaccc	2100
gaaggcacct	tggccagatc	cccattccatc	gacagcattc	agaaaagaccc	cagggagttt	2160
ggatggagag	accggagct	gcctgaagtg	atacagatgt	tacagcacca	gttcccttca	2220
gtccagtc	atgctgcagc	ttacctgcaa	cacctctgtt	ttggagacaa	taaaattaag	2280
gcagagataa	ggagacaagg	agggatacag	ctcctggtgg	acctgctgga	tcaccgaatg	2340
acagaagtcc	accgtagtgc	ctgtgggct	ctgaggaacc	tggtgtatgg	gaaggccaat	2400
gatgataaca	aaatcgccct	aaaaaactgt	ggtggtatcc	cagcgctggt	gagactcctt	2460
cgcaagacca	cagacctgga	gatccggag	ctggtcacag	gagtccttg	gaacctctca	2520
tcatgtatg	cactcaaataat	gccaatcatc	caggacgccc	tggcagtgt	gaccaatgcg	2580
gtgattatcc	ctcaactcggg	ctgggagaat	tcacctttc	aggatgatcg	aaaaatacag	2640
ctgcattcat	cacaggtgct	gcmcacgccc	actgggtgcc	taaggaatgt	aagttcagct	2700
ggagaggagg	cccgccgaag	gatcgggag	tgtatggc	tcacggatgc	cttgctgtac	2760
gtgatccagt	ctgcacttggg	gagcagttag	atcgatagca	agaccgttga	aaactgtgt	2820
tgcatcttga	ggAACCTCTC	ctaccggcta	gcagcagaaa	cgtctcaggg	acagcacatg	2880
ggcacagacg	agctggacgg	gctgctctgc	ggggagacca	acggcaaaaga	cacagagagt	2940
tctgggtgt	ggggcaagaa	gaagaagaaa	aagaaatccc	aggaccagtg	ggatggagta	3000
ggacctttc	cagactgtgc	agagccacca	aaagggatcc	agatgctgt	gcacccgtcc	3060
atagtcaaac	cctacctcac	actgctctct	gagtgctcaa	acccagacac	gcttggaaagg	3120
gcagcggcgc	ccctgcagaa	cttggctgca	gggagcttga	agggctggc	tgaggatgtg	3180
gcaggcatgg	cgtatgcct	acgttcactg	ccagaggggg	ctccctgcct	gccacagtgg	3240
tccgtgtata	tccgagctgc	tgtccggaaa	gagaaaggcc	tgcccattct	tgtggagctc	3300
ctccgaatag	acaatgaccc	tgttagtgt	gcagtggcca	cagcacttcg	gaacatggcc	3360
ctcgatgtca	gaaacaagg	actcattggc	aagtatgcca	tgcgagacct	ggtccaccgg	3420
cttcctgtgt	gaaacaacag	caacaactcg	gggagcaagg	ccatgtcaga	tgacaccgtg	3480
acggccgtgt	gctgcaccct	gcatgaagtg	atcaccaaga	acatggagaa	tgccaaggcc	3540
ttacggatg	ctgggtggcat	cgagaagttg	gtcggcatct	ctaaaagcaa	aggagacaag	3600
cactctccaa	agttggtcaa	ggctgcttct	caggtcttaa	acagcatgt	gcagtatcgc	3660
gatctgagga	gtctctacaa	gaaggatgga	tggtcacaat	atcactttgt	agcctcatct	3720
tcaaccatcg	agagggatcg	acaaaggccc	tactcctcct	cccgacacc	ctccatctct	3780
cccgtgcgt	tgtctcccaa	caaccgctca	gcaagtgc	cagttcacc	tcgggaaatg	3840
atcagcctca	aagaaaggaa	gacggactac	gagtccgctg	gcaacaacgc	cacttaccac	3900
gaaactaaag	gagaacacac	ctccagaaaa	gacaccatga	cagctaaaa	cactggagtt	3960
tcaacttgt	acaggaattc	atacggtgcc	cccgtgaag	acatcaaaca	gaaccaggtt	4020
tccacacagc	ctgtccctca	ggagcccgac	aggaaagact	acgagaccta	ccagcccttt	4080
cgaaattcca	cacgaaattt	tgtatgatcc	ttctttgagg	accaggtcca	ccaccggccct	4140
ccagccagcg	agtacaccat	gcacctgggc	ctcaagtcca	ctggcaacta	tgtcgactc	4200
tactctgcag	cccgctctta	cagtgaactg	aactatgaaa	cgagccacta	cccgccctcg	4260
cccgactcct	gggtgttaagg	agccaggaca	cgaggcactc	cggggacagt	gcatgtgcat	4320
gcatacacca	caggacattt	tgtttcttt	tttctttct	tttctttgt	tttttttttt	4380
ttttcttcc	ctgcaaattt	agtttggtaa	agcctgttcc	gttaggaaggc	tgtgataacc	4440
aggaagaaat	actcagagct	attttagaaa	gctaaaatga	atcaagagtt	aactgggaaa	4500
tcgataggaa	gctaaacgc	atcctaattt	tgaccgcatt	caacaccttt	ctagttgaa	4560
ctatagcatt	ttgaaaagtgc	tttatagtc	ggtgaggctg	aaggttaggag	agaggagaca	4620
gtcagggtgg	tggcgctggt	tatcgctaag	cacaagacag	actagttac	acactgtggg	4680

gacggcttct cacgctttgt ttactctctt catccgtgtg actctaggct tcaagttgca	4740
ttggggttcc tctgtacagc aagacgtctc ttgcctttt ttaatgcatt gttgtaaagt	4800
attcgatgtat cattacagat taaagacgaa gagtgcatgg tgatatattac accaatgcca	4860
ctgtgtttcc tcatcaatgg ttctaaatat tgcttcatt tcaaactttt gaaagatgtat	4920
tgggtttcca atttctttt ttttttctt tctcccagta tgttttaaca aaaaaggaaaa	4980
aaaaaaaaacag gaaaaaaaaa	4998

<210> 6
<211> 1247
<212> PRT
<213> mouse

<400> 6	
Met Phe Ala Arg Lys Gln Ser Gly Ala Ala Pro Phe Gly Ala Met Pro	
1 5 10 15	
Val Pro Asp Gln Pro Pro Ser Ala Ser Glu Lys Asn Ser Ser Leu Ser	
20 25 30	
Pro Gly Leu Asn Thr Ser Asn Gly Asp Gly Ser Glu Thr Glu Thr Thr	
35 40 45	
Ser Ala Ile Leu Ala Ser Val Lys Glu Gln Glu Leu Gln Phe Glu Arg	
50 55 60	
Leu Thr Arg Glu Leu Glu Ala Glu Arg Gln Ile Val Ala Ser Gln Leu	
65 70 75 80	
Glu Arg Cys Lys Leu Gly Ser Glu Thr Gly Ser Met Ser Ser Ile Ser	
85 90 95	
Ser Ala Gly Glu Gln Phe His Trp Gln Thr Gln Asp Gly Gln Lys Asp	
100 105 110	
Ile Glu Asp Glu Leu Thr Thr Gly Leu Glu Leu Val Asp Ser Cys Ile	
115 120 125	
Arg Ser Leu Gln Glu Ser Gly Ile Leu Asp Pro Gln Asp Tyr Ser Thr	
130 135 140	
Ser Glu Arg Pro Ser Leu Leu Ser Gln Ser Ala Leu Gln Leu Asn Ser	
145 150 155 160	
Lys Pro Glu Gly Ser Phe Gln Tyr Pro Ala Ser Tyr His Ser Asn Gln	
165 170 175	
Thr Leu Ala Leu Gly Asp Thr Ala Pro Ser Gln Leu Pro Ala Arg Ser	
180 185 190	
Thr Gln Ala Arg Ala Ala Gly Gln Ser Phe Ser Gln Gly Thr Thr Gly	
195 200 205	
Arg Ala Gly His Leu Ala Gly Ser Glu Pro Ala Pro Pro Pro Pro	
210 215 220	
Pro Arg Glu Pro Phe Ala Pro Ser Leu Gly Ser Ala Phe His Leu Pro	
225 230 235 240	
Asp Ala Pro Pro Ala Ala Ala Leu Tyr Tyr Ser Ser Ser Thr Leu	
245 250 255	
Pro Ala Pro Pro Arg Gly Gly Ser Pro Leu Thr Thr Thr Gln Gly Gly	
260 265 270	
Ser Pro Thr Lys Leu Gln Arg Gly Gly Ser Ala Pro Glu Gly Ala Ala	
275 280 285	
Tyr Ala Ala Pro Arg Gly Ser Ser Pro Lys Gln Ser Pro Ser Arg Leu	
290 295 300	
Ala Lys Ser Tyr Ser Thr Ser Ser Pro Ile Asn Ile Val Val Ser Ser	
305 310 315 320	

Ala Gly Leu Ser Pro Ile Arg Val Thr Ser Pro Pro Thr Val Gln Ser
 325 330 335
 Thr Ile Ser Ser Ser Pro Ile His Gln Leu Ser Ser Thr Ile Gly Thr
 340 345 350
 Tyr Ala Thr Leu Ser Pro Thr Lys Arg Leu Val His Ala Ser Glu Gln
 355 360 365
 Tyr Ser Lys His Ser Gln Glu Leu Tyr Ala Thr Ala Thr Leu Gln Arg
 370 375 380
 Pro Gly Ser Leu Ala Ala Gly Ser Arg Ala Ser Tyr Ser Ser Gln His
 385 390 395 400
 Gly His Leu Ala Pro Glu Leu Arg Ala Leu Gln Ser Pro Glu His His
 405 410 415
 Ile Asp Pro Ile Tyr Glu Asp Arg Val Tyr Gln Lys Pro Pro Met Arg
 420 425 430
 Ser Leu Ser Gln Ser Gln Gly Asp Pro Leu Pro Pro Ala His Thr Gly
 435 440 445
 Thr Phe Arg Thr Ser Thr Ala Pro Ser Ser Pro Gly Val Asp Ser Val
 450 455 460
 Pro Leu Gln Arg Thr Gly Ser Gln His Gly Pro Gln Asn Ala Ala Ala
 465 470 475 480
 Ala Thr Phe Gln Arg Ala Ser Tyr Ala Ala Gly Pro Ala Ser Asn Tyr
 485 490 495
 Ala Asp Pro Tyr Arg Gln Leu Gln Tyr Cys Ala Ser Val Asp Ser Pro
 500 505 510
 Tyr Ser Lys Ser Gly Pro Ala Leu Pro Pro Glu Gly Thr Leu Ala Arg
 515 520 525
 Ser Pro Ser Ile Asp Ser Ile Gln Lys Asp Pro Arg Glu Phe Gly Trp
 530 535 540
 Arg Asp Pro Glu Leu Pro Glu Val Ile Gln Met Leu Gln His Gln Phe
 545 550 555 560
 Pro Ser Val Gln Ser Asn Ala Ala Ala Tyr Leu Gln His Leu Cys Phe
 565 570 575
 Gly Asp Asn Lys Ile Lys Ala Glu Ile Arg Arg Gln Gly Gly Ile Gln
 580 585 590
 Leu Leu Val Asp Leu Leu Asp His Arg Met Thr Glu Val His Arg Ser
 595 600 605
 Ala Cys Gly Ala Leu Arg Asn Leu Val Tyr Gly Lys Ala Asn Asp Asp
 610 615 620
 Asn Lys Ile Ala Leu Lys Asn Cys Gly Gly Ile Pro Ala Leu Val Arg
 625 630 635 640
 Leu Leu Arg Lys Thr Thr Asp Leu Glu Ile Arg Glu Leu Val Thr Gly
 645 650 655
 Val Leu Trp Asn Leu Ser Ser Cys Asp Ala Leu Lys Met Pro Ile Ile
 660 665 670
 Gln Asp Ala Leu Ala Val Leu Thr Asn Ala Val Ile Ile Pro His Ser
 675 680 685
 Gly Trp Glu Asn Ser Pro Leu Gln Asp Asp Arg Lys Ile Gln Leu His
 690 695 700
 Ser Ser Gln Val Leu Arg Asn Ala Thr Gly Cys Leu Arg Asn Val Ser
 705 710 715 720
 Ser Ala Gly Glu Glu Ala Arg Arg Arg Met Arg Glu Cys Asp Gly Leu
 725 730 735
 Thr Asp Ala Leu Leu Tyr Val Ile Gln Ser Ala Leu Gly Ser Ser Glu

	740		745		750	
Ile Asp Ser Lys Thr Val Glu Asn Cys Val Cys Ile Leu Arg Asn Leu						
755			760		765	
Ser Tyr Arg Leu Ala Ala Glu Thr Ser Gln Gly Gln His Met Gly Thr						
770			775		780	
Asp Glu Leu Asp Gly Leu Leu Cys Gly Glu Thr Asn Gly Lys Asp Thr						
785			790		795	
Glu Ser Ser Gly Cys Trp Gly Lys Lys Lys Lys Lys Ser Gln						
805			810		815	
Asp Gln Trp Asp Gly Val Gly Pro Leu Pro Asp Cys Ala Glu Pro Pro						
820			825		830	
Lys Gly Ile Gln Met Leu Trp His Pro Ser Ile Val Lys Pro Tyr Leu						
835			840		845	
Thr Leu Leu Ser Glu Cys Ser Asn Pro Asp Thr Leu Glu Gly Ala Ala						
850			855		860	
Gly Ala Leu Gln Asn Leu Ala Ala Gly Ser Trp Lys Gly Trp Ala Glu						
865			870		875	
Asp Val Ala Gly Met Ala Tyr Ala Leu Arg Ser Leu Pro Glu Gly Ala						
885			890		895	
Pro Cys Leu Pro Gln Trp Ser Val Tyr Ile Arg Ala Ala Val Arg Lys						
900			905		910	
Glu Lys Gly Leu Pro Ile Leu Val Glu Leu Leu Arg Ile Asp Asn Asp						
915			920		925	
Arg Val Val Cys Ala Val Ala Thr Ala Leu Arg Asn Met Ala Leu Asp						
930			935		940	
Val Arg Asn Lys Glu Leu Ile Gly Lys Tyr Ala Met Arg Asp Leu Val						
945			950		955	
His Arg Leu Pro Gly Gly Asn Asn Ser Asn Asn Ser Gly Ser Lys Ala						
965			970		975	
Met Ser Asp Asp Thr Val Thr Ala Val Cys Cys Thr Leu His Glu Val						
980			985		990	
Ile Thr Lys Asn Met Glu Asn Ala Lys Ala Leu Arg Asp Ala Gly Gly						
995			1000		1005	
Ile Glu Lys Leu Val Gly Ile Ser Lys Ser Lys Gly Asp Lys His Ser						
1010			1015		1020	
Pro Lys Val Val Lys Ala Ala Ser Gln Val Leu Asn Ser Met Trp Gln						
1025			1030		1035	
Tyr Arg Asp Leu Arg Ser Leu Tyr Lys Lys Asp Gly Trp Ser Gln Tyr						
1045			1050		1055	
His Phe Val Ala Ser Ser Ser Thr Ile Glu Arg Asp Arg Gln Arg Pro						
1060			1065		1070	
Tyr Ser Ser Ser Arg Thr Pro Ser Ile Ser Pro Val Arg Val Ser Pro						
1075			1080		1085	
Asn Asn Arg Ser Ala Ser Ala Pro Ala Ser Pro Arg Glu Met Ile Ser						
1090			1095		1100	
Leu Lys Glu Arg Lys Thr Asp Tyr Glu Ser Ala Gly Asn Asn Ala Thr						
1105			1110		1115	
Tyr His Gly Thr Lys Gly Glu His Thr Ser Arg Lys Asp Thr Met Thr						
1125			1130		1135	
Ala Gln Asn Thr Gly Val Ser Thr Leu Tyr Arg Asn Ser Tyr Gly Ala						
1140			1145		1150	
Pro Ala Glu Asp Ile Lys Gln Asn Gln Val Ser Thr Gln Pro Val Pro						
1155			1160		1165	

Gln Glu Pro Ser Arg Lys Asp Tyr Glu Thr Tyr Gln Pro Phe Pro Asn
1170 1175 1180
Ser Thr Arg Asn Tyr Asp Glu Ser Phe Phe Glu Asp Gln Val His His
1185 1190 1195 120
Arg Pro Pro Ala Ser Glu Tyr Thr Met His Leu Gly Leu Lys Ser Thr
1205 1210 1215
Gly Asn Tyr Val Asp Phe Tyr Ser Ala Ala Arg Pro Tyr Ser Glu Leu
1220 1225 1230
Asn Tyr Glu Thr Ser His Tyr Pro Ala Ser Pro Asp Ser Trp Val
1235 1240 1245